Skip to content

Efficacy of using scalp cooling caps in prevention of chemotherapy-induced alopecia

Evaluation of using scalp cooling caps in prevention of chemotherapy-induced alopecia

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20141102019783N4
Enrollment
60
Registered
2019-01-13
Start date
2015-03-21
Completion date
Unknown
Last updated
2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast malignancy. Malignant neoplasm of breast

Interventions

Intervention 1: Using Scalp Cooling Cap 30 minutes before, during and up to 2.5 hours after chemotherapy with "Adriamycin and Cyclophosphamide" in breast cancer. Intervention 2: Using Scalp Cooling Ca

Sponsors

Vice chancellor for research, Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: consent for using the cap and filling on the questionnaire using chemotherapy regimens resulting in total alopecia including: 1. Doxorobicin plus cyclophosphamide followed by one of the Taxane drugs (in one, two or three-week regimens) 2. BEP regimen in gonadal malignanciy 3. FEC (5Fu-Epirubicin -cyclophosphamaid) regimen 4. VAC (vincristin-Doxorobicin -cyclophosphamaid) regimen in sarcomas performance higher than 70% age between 18 to 75 years

Exclusion criteria

Exclusion criteria: Melanoma Blood malignancies Liver or kidney dysfunction Migraine History of cryoglobulinemia Systemic lupus erythematosus No consent for using the caps

Design outcomes

Primary

MeasureTime frame
Alopecia. Timepoint: prior to each chemotherapy cycle. Method of measurement: visual inspection and questionnaire based on WHO alopecia grading.

Secondary

MeasureTime frame
Headache. Timepoint: following every cycle of chemotherapy. Method of measurement: qestionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMitra Fazl Ersi

Mashhad University of Medical Sciences

mitrafazlersi@gmail.com+98 51 3846 1518

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026